Literature DB >> 27122764

Long-Term Prognosis in Recipients of Implantable Cardioverter-Defibrillators for Secondary Preventions in Taiwan - A Multicenter Registry Study.

Tze-Fan Chao1, Chih-Hung Lai2, Ta-Chuan Tuan3, Tsu-Juey Wu4, Jin-Long Huang4, Chuen-Wang Chiou5, Hsiang-Chiang Hsiao5, Yenn-Jiang Lin1, Jo-Nan Liao1, Chi-Woon Kong6, Shih-Ann Chen1.   

Abstract

BACKGROUND: The use of an implantable cardioverter-defibrillator (ICD) has a proven capacity to prevent sudden cardiac death (SCD), and can also improve survival duration in well-selected patients. The goal of the present study was to investigate the long-term prognosis and predictors of mortalities among ICD recipients in Taiwan.
METHODS: From 1998 to 2009, 238 consecutive patients who experienced SCDs or life-threatening ventricular tachyarrhythmias without correctable causes and received ICD implantations in 3 medical centers (Taipei, Taichung and Kaohsiung Veterans General Hospital) were enrolled in this study. The clinical endpoint was defined as the occurrence of all-cause mortality during the follow-up.
RESULTS: The mean age of the patients was 63.0 ± 15.3 years, and 76.5% of them were male. Ischemic cardiomyopathy was the leading cause for the ICD implantations (39.1%). During the mean follow-up duration of 36.8 ± 29.8 months, there were 48 patients (20.2%) who died. Patients with structural heart diseases had a higher mortality rate than those without such diseases. Additionally, old age, low left ventricular ejection fraction (LVEF) and a history of diabetes mellitus (DM) were significant predictors of mortality. The optimal cutoff values for age (70 years) and LVEF (40%) in predicting mortality were further identified using the receiver operating characteristic curves.
CONCLUSIONS: Based on the ICD registry from 3 medical centers in Taiwan, the annual mortality rate was around 6.6% and was higher in those patients with structural heart diseases. We observed that old age, low LVEF and a history of DM were significant predictors of mortality. KEY WORDS: Implantable cardioverter-defibrillator; Mortality; Predictor; Taiwan.

Entities:  

Year:  2014        PMID: 27122764      PMCID: PMC4804817     

Source DB:  PubMed          Journal:  Acta Cardiol Sin        ISSN: 1011-6842            Impact factor:   2.672


  14 in total

1.  Rising rates of cardiac rhythm management device infections in the United States: 1996 through 2003.

Authors:  Andrew Voigt; Alaa Shalaby; Samir Saba
Journal:  J Am Coll Cardiol       Date:  2006-07-12       Impact factor: 24.094

2.  Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.

Authors:  Arthur J Moss; Wojciech Zareba; W Jackson Hall; Helmut Klein; David J Wilber; David S Cannom; James P Daubert; Steven L Higgins; Mary W Brown; Mark L Andrews
Journal:  N Engl J Med       Date:  2002-03-19       Impact factor: 91.245

3.  Prediction of mortality in clinical practice for medicare patients undergoing defibrillator implantation for primary prevention of sudden cardiac death.

Authors:  Kenneth C Bilchick; George J Stukenborg; Sandeep Kamath; Alan Cheng
Journal:  J Am Coll Cardiol       Date:  2012-09-26       Impact factor: 24.094

4.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

Authors:  Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

5.  A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators.

Authors:  A E Buxton; K L Lee; J D Fisher; M E Josephson; E N Prystowsky; G Hafley
Journal:  N Engl J Med       Date:  1999-12-16       Impact factor: 91.245

6.  Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator.

Authors:  Douglas K Owens; Gillian D Sanders; Paul A Heidenreich; Kathryn M McDonald; Mark A Hlatky
Journal:  Am Heart J       Date:  2002-09       Impact factor: 4.749

7.  Cost-effectiveness of the implantable cardioverter defibrillator.

Authors:  Mark A Hlatky; Gillian D Sanders; Douglas K Owens
Journal:  Card Electrophysiol Rev       Date:  2003-12

8.  Development of atrial fibrillation in patients with atrioventricular block after atrioventricular synchronized pacing.

Authors:  Chi-Woon Kong; Wen-Chung Yu; Shih-Ann Chen; Yenn-Jiang Lin; Chun-Yao Huang; Sheng-Liang Chung
Journal:  Pacing Clin Electrophysiol       Date:  2004-03       Impact factor: 1.976

9.  Implantable cardioverter defibrillator therapy: ten years experience in a medical center.

Authors:  Tien-En Chen; Chun-Chieh Wang; Shang-Hung Chang; San-Jou Yeh; Delon Wu
Journal:  Chang Gung Med J       Date:  2008 Jan-Feb

10.  Predictors of early mortality in implantable cardioverter-defibrillator recipients.

Authors:  Kenneth M Stein; Suneet Mittal; F Roosevelt Gilliam; David M Gilligan; Qian Zhong; Stacia Merkel Kraus; Timothy E Meyer
Journal:  Europace       Date:  2009-03-11       Impact factor: 5.214

View more
  3 in total

Review 1.  Implantation of Implantable Cardioverter Defibrillators in Kazakhstan.

Authors:  Temirkhan Begisbayev; Lyazzat Kosherbayeva; Valikhan Akhmetov; Dmitry Khvan; Marzhan Brimzhanova
Journal:  Glob Heart       Date:  2022-05-10

2.  Long-Term Follow-Up of Catheter Ablation of Ventricular Arrhythmias: Experiences from a Tertiary Referral Center in Taiwan.

Authors:  Fa-Po Chung; Yenn-Jiang Lin; Shih-Lin Chang; Li-Wei Lo; Yu-Feng Hu; Yun-Yu Chen; Chuen-Wang Chiou; Shih-Ann Chen
Journal:  Acta Cardiol Sin       Date:  2015-01       Impact factor: 2.672

3.  Influence of diabetes on mortality and ICD therapies in ICD recipients: a systematic review and meta-analysis of 162,780 patients.

Authors:  Hualong Liu; Jinzhu Hu; Wen Zhuo; Rong Wan; Kui Hong
Journal:  Cardiovasc Diabetol       Date:  2022-07-29       Impact factor: 8.949

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.